No Data
No Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
Journey Medical Management to Meet Virtually With B. Riley
B.Riley Financial Maintains Journey Medical(DERM.US) With Buy Rating, Raises Target Price to $9
B. Riley Adjusts Journey Medical Price Target to $9 From $8, Maintains Buy Rating
US Manufacturing Index Rises To 43, Highest Since 2020
US$9.75 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
No Data
Xyno : The approval paved the way for the price to go up. It is. It is not unusual to see a price drop on approval, as shorters want to protect their money. This stock is looking at a 10-12 target within a year.
HannChau OP Xyno : hopefully but still dunno when is end date.for shorties as this few days still shorties concur the stock.